See the published version of this preprint at Stem Cell Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Amy L. Lightner
Cleveland Clinic
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Mesenchymal stem cells (MSCs) are a well-established immunosuppressive agent which can also promote tissue repair and regeneration. Recent studies have demonstrated MSCs as a novel therapeutic for inflammatory bowel disease (IBD), a chronic idiopathic inflammatory disorder of the gastrointestinal tract. However, the precise role of MSCs in regulating immune-responses is controversial, and its significance in the pathogenesis of IBD uncertain. In addition, MSCs’ acellular product, extracellular vesicles (EVs), may also play an important role in the armamentarium of therapeutics, but how EVs compare to MSCs remains undefined due to the lack of side-by-side comparative investigation. We herein compared MSCs and their associated EVs side-by-side using a DSS-induced colitis model.
Methods: A DSS-induced colitis model was used. At Day 4, mice received adipose derived MSCs, MSC derived EVs, or placebo. Weight loss, stool consistency and hematochezia was charted. At day 8, murine colons were harvested, histologic analysis performed, and serum/tissue cytokine analysis conducted.
Results: MSCs and EVs demonstrated equivalent immunosuppressive functions with DSS-treated mice through decreased colonic lymphocyte infiltration and attenuated disease severity after both MSC and EV treatment. Furthermore, both MSCs and EVs have an equivalent ability to inhibit inflammation in the DSS colitis model.
Conclusions: These results suggest that (i) both MSCs and EVs are effective therapeutic candidates for a DSS-induced mouse colitis model, (ii) MSCs and EVs have similar immunosuppressive and anti-inflammatory functions, and (iii) EVs may present a novel future therapeutic for the treatment of IBD.
Keywords
Mesenchymal Stem Cells, Extracellular Vesicles, Inflammatory Bowel Disease, Murine Colitis Model, therapy
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Stem Cell Research & Therapy.
No community comments so far
Editor assigned
On 08 Nov, 2020
Editorial decision: Accept
On 08 Nov, 2020
Submission checks complete
On 08 Nov, 2020
Editor invited
On 08 Nov, 2020
No comments provided
Review #1 received
Received 18 Oct, 2020
Reviewer #1 agreed
On 15 Oct, 2020
Reviewers invited
Invitations sent on 12 Oct, 2020
Editor assigned
On 11 Oct, 2020
Submission checks complete
On 10 Oct, 2020
Editor invited
On 10 Oct, 2020
Version 1
Posted 03 Sep, 2020
No comments provided
Editorial decision: Major Revision
On 21 Sep, 2020
Review #3 received
Received 20 Sep, 2020
Reviewer #4 agreed
On 09 Sep, 2020
Reviewer #3 agreed
On 06 Sep, 2020
Review #1 received
Received 05 Sep, 2020
Reviewer #2 agreed
On 05 Sep, 2020
Review #2 received
Received 05 Sep, 2020
Reviewers invited
Invitations sent on 04 Sep, 2020
Reviewer #1 agreed
On 04 Sep, 2020
Editor assigned
On 03 Sep, 2020
Editor invited
On 02 Sep, 2020
Submission checks complete
On 02 Sep, 2020
First submitted
On 31 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Stem Cell Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Amy L. Lightner
Cleveland Clinic
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Stem Cell Research & Therapy.
No community comments so far
Editor assigned
On 08 Nov, 2020
Editorial decision: Accept
On 08 Nov, 2020
Submission checks complete
On 08 Nov, 2020
Editor invited
On 08 Nov, 2020
No comments provided
Review #1 received
Received 18 Oct, 2020
Reviewer #1 agreed
On 15 Oct, 2020
Reviewers invited
Invitations sent on 12 Oct, 2020
Editor assigned
On 11 Oct, 2020
Submission checks complete
On 10 Oct, 2020
Editor invited
On 10 Oct, 2020
Version 1
Posted 03 Sep, 2020
No comments provided
Editorial decision: Major Revision
On 21 Sep, 2020
Review #3 received
Received 20 Sep, 2020
Reviewer #4 agreed
On 09 Sep, 2020
Reviewer #3 agreed
On 06 Sep, 2020
Review #1 received
Received 05 Sep, 2020
Reviewer #2 agreed
On 05 Sep, 2020
Review #2 received
Received 05 Sep, 2020
Reviewers invited
Invitations sent on 04 Sep, 2020
Reviewer #1 agreed
On 04 Sep, 2020
Editor assigned
On 03 Sep, 2020
Editor invited
On 02 Sep, 2020
Submission checks complete
On 02 Sep, 2020
First submitted
On 31 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Stem Cell Research & Therapy.
Background: Mesenchymal stem cells (MSCs) are a well-established immunosuppressive agent which can also promote tissue repair and regeneration. Recent studies have demonstrated MSCs as a novel therapeutic for inflammatory bowel disease (IBD), a chronic idiopathic inflammatory disorder of the gastrointestinal tract. However, the precise role of MSCs in regulating immune-responses is controversial, and its significance in the pathogenesis of IBD uncertain. In addition, MSCs’ acellular product, extracellular vesicles (EVs), may also play an important role in the armamentarium of therapeutics, but how EVs compare to MSCs remains undefined due to the lack of side-by-side comparative investigation. We herein compared MSCs and their associated EVs side-by-side using a DSS-induced colitis model.
Methods: A DSS-induced colitis model was used. At Day 4, mice received adipose derived MSCs, MSC derived EVs, or placebo. Weight loss, stool consistency and hematochezia was charted. At day 8, murine colons were harvested, histologic analysis performed, and serum/tissue cytokine analysis conducted.
Results: MSCs and EVs demonstrated equivalent immunosuppressive functions with DSS-treated mice through decreased colonic lymphocyte infiltration and attenuated disease severity after both MSC and EV treatment. Furthermore, both MSCs and EVs have an equivalent ability to inhibit inflammation in the DSS colitis model.
Conclusions: These results suggest that (i) both MSCs and EVs are effective therapeutic candidates for a DSS-induced mouse colitis model, (ii) MSCs and EVs have similar immunosuppressive and anti-inflammatory functions, and (iii) EVs may present a novel future therapeutic for the treatment of IBD.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...